 Christopher Manuel
Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Corynebacterium Infections | 9 | 2024 | 42 | 5.600 |
Why?
| | Corynebacterium | 10 | 2024 | 49 | 5.460 |
Why?
| | Housing, Animal | 6 | 2024 | 46 | 2.240 |
Why?
| | Rodent Diseases | 4 | 2020 | 28 | 1.860 |
Why?
| | Mice, Nude | 7 | 2024 | 677 | 1.550 |
Why?
| | Mice, Inbred NOD | 5 | 2023 | 610 | 1.080 |
Why?
| | Rodentia | 2 | 2023 | 62 | 0.850 |
Why?
| | Culture Media | 1 | 2024 | 163 | 0.830 |
Why?
| | Animal Husbandry | 4 | 2024 | 37 | 0.770 |
Why?
| | Skin Diseases | 1 | 2023 | 151 | 0.710 |
Why?
| | Mice | 12 | 2024 | 18261 | 0.670 |
Why?
| | Ventilation | 2 | 2024 | 46 | 0.650 |
Why?
| | Drinking Water | 1 | 2022 | 91 | 0.650 |
Why?
| | Chinchilla | 1 | 2020 | 35 | 0.630 |
Why?
| | Environmental Monitoring | 3 | 2024 | 374 | 0.630 |
Why?
| | Chlorine Compounds | 1 | 2019 | 11 | 0.610 |
Why?
| | Decontamination | 1 | 2019 | 31 | 0.590 |
Why?
| | Oxides | 1 | 2019 | 49 | 0.590 |
Why?
| | Disinfectants | 1 | 2019 | 49 | 0.580 |
Why?
| | Anti-Bacterial Agents | 4 | 2023 | 1928 | 0.560 |
Why?
| | Animals | 20 | 2024 | 37948 | 0.560 |
Why?
| | Streptococcal Infections | 1 | 2020 | 170 | 0.530 |
Why?
| | Heterografts | 1 | 2017 | 143 | 0.490 |
Why?
| | Neoplasms, Experimental | 1 | 2017 | 167 | 0.470 |
Why?
| | Air Microbiology | 1 | 2016 | 50 | 0.450 |
Why?
| | Gastrointestinal Microbiome | 1 | 2023 | 771 | 0.430 |
Why?
| | Animals, Laboratory | 2 | 2024 | 22 | 0.420 |
Why?
| | Microbiota | 1 | 2022 | 782 | 0.410 |
Why?
| | Air Pollution, Indoor | 1 | 2016 | 182 | 0.400 |
Why?
| | Mice, SCID | 3 | 2023 | 368 | 0.390 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2020 | 339 | 0.380 |
Why?
| | Sanitation | 2 | 2023 | 56 | 0.300 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 18 | 0.270 |
Why?
| | Sentinel Surveillance | 1 | 2008 | 46 | 0.270 |
Why?
| | Norovirus | 1 | 2008 | 22 | 0.270 |
Why?
| | Tissue Culture Techniques | 1 | 2024 | 82 | 0.210 |
Why?
| | Animal Feed | 1 | 2024 | 55 | 0.210 |
Why?
| | Random Allocation | 2 | 2024 | 366 | 0.200 |
Why?
| | Amoxicillin | 1 | 2023 | 35 | 0.200 |
Why?
| | Ammonia | 1 | 2023 | 65 | 0.190 |
Why?
| | Stereotyped Behavior | 1 | 2022 | 22 | 0.180 |
Why?
| | Photoperiod | 1 | 2022 | 55 | 0.180 |
Why?
| | Soil | 1 | 2024 | 216 | 0.170 |
Why?
| | Streptococcus equi | 1 | 2020 | 4 | 0.160 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2020 | 16 | 0.160 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2020 | 58 | 0.160 |
Why?
| | Age Factors | 2 | 2024 | 3329 | 0.160 |
Why?
| | Zebrafish | 1 | 2024 | 532 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 1 | 2021 | 373 | 0.150 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 564 | 0.150 |
Why?
| | Gases | 1 | 2019 | 53 | 0.150 |
Why?
| | Chlorine | 1 | 2019 | 62 | 0.150 |
Why?
| | Equipment Contamination | 1 | 2019 | 71 | 0.150 |
Why?
| | Immunocompromised Host | 1 | 2020 | 202 | 0.140 |
Why?
| | Animals, Newborn | 1 | 2020 | 890 | 0.130 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 3523 | 0.120 |
Why?
| | Diet | 1 | 2024 | 1270 | 0.120 |
Why?
| | Laboratory Animal Science | 1 | 2016 | 3 | 0.120 |
Why?
| | Sterilization | 1 | 2016 | 24 | 0.120 |
Why?
| | Dermatitis | 1 | 2016 | 19 | 0.120 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2922 | 0.120 |
Why?
| | Female | 7 | 2024 | 78304 | 0.110 |
Why?
| | Rats | 1 | 2023 | 5570 | 0.100 |
Why?
| | DNA, Bacterial | 1 | 2016 | 347 | 0.100 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4539 | 0.100 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 33 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 243 | 0.080 |
Why?
| | Estrogens | 1 | 2012 | 364 | 0.070 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 400 | 0.070 |
Why?
| | Mice, Inbred ICR | 1 | 2008 | 113 | 0.070 |
Why?
| | Prospective Studies | 1 | 2020 | 7994 | 0.070 |
Why?
| | Pregnancy | 1 | 2020 | 7122 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 973 | 0.060 |
Why?
| | Bedding and Linens | 1 | 2024 | 11 | 0.050 |
Why?
| | Feces | 1 | 2008 | 513 | 0.050 |
Why?
| | Environmental Health | 1 | 2024 | 39 | 0.050 |
Why?
| | Gels | 1 | 2024 | 85 | 0.050 |
Why?
| | RNA, Viral | 1 | 2008 | 689 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2008 | 672 | 0.050 |
Why?
| | United States | 1 | 2021 | 16018 | 0.050 |
Why?
| | Fertility | 1 | 2024 | 166 | 0.050 |
Why?
| | Weaning | 1 | 2022 | 51 | 0.040 |
Why?
| | Gerbillinae | 1 | 2022 | 72 | 0.040 |
Why?
| | Attitude | 1 | 2023 | 260 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2365 | 0.040 |
Why?
| | Humans | 3 | 2024 | 144667 | 0.040 |
Why?
| | Male | 3 | 2024 | 72431 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 18 | 0.020 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 104 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 191 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 324 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5870 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 192 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 516 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 881 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 751 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 319 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 925 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 407 | 0.020 |
Why?
| | Transcriptome | 1 | 2012 | 1036 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5185 | 0.010 |
Why?
|
|
Manuel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|